The full approval was based on the confirmatory phase 3 MIRASOL trial, which showed that Elahere resulted in a 33% reduction in risk of death and a 35% reduction in the risk of cancer progression.
The FDA has granted full approval for Elahere (mirvetuximab soravtansine-gynx) to treat adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is indicated for women who have received one to three prior systemic treatment regimens.
Elahere had been granted accelerated approval in November 2022. It is an antibody-drug conjugate targeted against folate receptor alpha, a cell-surface protein highly expressed in ovarian cancer. About 35% to 40% of ovarian cancer patients express high levels of folate receptor alpha.
Elahere was developed by ImmunoGen, which AbbVie acquired in February 2024. When Elahere launched, the wholesale acquisition cost was $6,220 for one vial, and patients, typically undergo the use of three to four vials per cycle. This translates to $18,660 to $24,800 per treatment cycle.
Related: FDA Grants Accelerated Approval of Novel Ovarian Cancer Therapy
The full approval is based on data from the confirmatory phase 3 MIRASOL trial, which showed that Elahere resulted in a 33% reduction in risk of death and a 35% reduction in the risk of cancer progression
The trial enrolled 453 patients and compared Elahere with investigator’s choice (IC) of chemotherapy. The primary end point was progression-free survival (PFS) by investigator assessment and key secondary endpoints included objective response rate (ORR) and overall survival (OS).
The label includes a boxed warning about ocular toxicity, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis (inflammation). The label also requires patients to have an ophthalmic exam every other cycle for the first eight cycles.
Other warnings includes the risk of severe, life-threatening interstitial lung disease, including pneumonitis, as well as peripheral neuropathy.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Read More